Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at https://www.facebook.com/jamescgreenwood.

Latest Posts

Updated Legal and Regulatory Frameworks Needed for Biosimilars

Jim Greenwood

Biosimilars raise novel and complex questions of science and law that require updated legal and regulatory frameworks. We call on the FDA to release final guidance on processes and scientific criteria for the approval of biosimilars, outline its approach to naming and labeling, and clarify its conditions for determining a biosimilar to be interchangeable with its reference biological. There has been positive momentum recently, however, we believe the appropriate way to develop policy on such Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Attacks on Venture Philanthropy Miss Mark Badly

Jim Greenwood

In a highly problematic op-ed in today’s New York Times, freelance journalist Llewellyn Hinkes-Jones attacked venture philanthropy and patient foundation funding of medical research, which has become a valuable source of funding for diseases which may not otherwise receive research dollars. Venture philanthropy organizations bring a singular focus and drive to the process of getting promising therapies from the laboratory bench to the patient as quickly and efficiently as possible, bringing hope – and results – to Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Wall Street Journal Highlights Promising Gene Therapy Advances

Jim Greenwood

Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American Society of Hematology. Two patients with beta-thalassemia, a genetic disorder which normally requires regular blood transfusions, have been able to forgo transfusions for at least five months following a gene therapy treatment from bluebird. The Wall Street Journal’s Ron Winslow reports: Bluebird bio’s treatment involves extracting blood stem cells from a patient, treating them with a functioning version of the defective Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

San Francisco Chronicle: High Drug Co-Pays Deny Needed Treatments

Jim Greenwood

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of ensuring access to treatments for debilitating diseases that are saving millions of patients from pain and possible death. Patients rightly expect their health insurance plan to cover the best medicines based on their unique needs, at an out-of-pocket cost that makes these therapies accessible. Insurance companies and their allies, seeking to deflect blame for increased premiums at a time of Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Welcome to San Diego!

Jim Greenwood

Welcome to the 2014 BIO International Convention. It has been an exciting and important year for our industry. Since we last met, we have seen record IPOs, important new approvals, exciting scientific advances and hard fought policy victories in Washington, DC and the states. But we all know that accomplishments don’t just happen by luck. They are the result of decades of hard work, long hours and repeated setbacks. So while it’s important to celebrate Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,